Controlling the biology of Interleukin-1 beta (IL-1β), which drives the progression of atherosclerosis (Libby et al., 2014; Libby and Hansson, 2015), leading to cardiovascular complications, has been of particular interest. This evidence concerns the gene IL1B and atherosclerosis.